FIA
ATRA icon

FNY Investment Advisers’s Atara Biotherapeutics ATRA Stock Holding History

FNY Investment Advisers’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-120
Closed -$4K – 477
2023
Q3 		$4K Buy
+120
New +$5.34K ﹤0.01% 469

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FNY Investment Advisers's ATRA Position: Q4 2023 in Review

FNY Investment Advisers sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 120 shares — an estimated $4K sold.

FNY Investment Advisers first reported a position in ATRA in Q3 2023 and held it in 1 quarter. The position peaked at $4K in Q3 2023. 89 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • FNY Investment Advisers reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 120 Atara Biotherapeutics shares in Q4 2023, an estimated $4K.
  • FNY Investment Advisers first reported a position in Atara Biotherapeutics in Q3 2023 and held it in 1 quarter.
  • FNY Investment Advisers's Atara Biotherapeutics position peaked at $4K in Q3 2023.
  • 89 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on FNY Investment Advisers's 13F filing for Q4 2023, filed 12 Jan 2024.